DK1923071T3 - Equint herpesvirusvaccine - Google Patents

Equint herpesvirusvaccine

Info

Publication number
DK1923071T3
DK1923071T3 DK08150506.7T DK08150506T DK1923071T3 DK 1923071 T3 DK1923071 T3 DK 1923071T3 DK 08150506 T DK08150506 T DK 08150506T DK 1923071 T3 DK1923071 T3 DK 1923071T3
Authority
DK
Denmark
Prior art keywords
equine herpesvirus
herpesvirus vaccine
vaccine
equine
herpesvirus
Prior art date
Application number
DK08150506.7T
Other languages
English (en)
Inventor
Mark W Mellencamp
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Application granted granted Critical
Publication of DK1923071T3 publication Critical patent/DK1923071T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK08150506.7T 2001-03-20 2002-01-23 Equint herpesvirusvaccine DK1923071T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/812,720 US6803041B2 (en) 2001-03-20 2001-03-20 Equine herpesvirus vaccine
EP02713437A EP1372712B1 (en) 2001-03-20 2002-01-23 Equine herpesvirus vaccine

Publications (1)

Publication Number Publication Date
DK1923071T3 true DK1923071T3 (da) 2013-08-26

Family

ID=25210428

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08150506.7T DK1923071T3 (da) 2001-03-20 2002-01-23 Equint herpesvirusvaccine
DK02713437T DK1372712T3 (da) 2001-03-20 2002-01-23 Vaccine mod equint herpesvirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02713437T DK1372712T3 (da) 2001-03-20 2002-01-23 Vaccine mod equint herpesvirus

Country Status (15)

Country Link
US (3) US6803041B2 (da)
EP (2) EP1923071B1 (da)
JP (2) JP4177112B2 (da)
KR (1) KR100840525B1 (da)
AR (2) AR032984A1 (da)
AT (1) ATE392903T1 (da)
CA (1) CA2441292C (da)
CY (1) CY1108200T1 (da)
DE (1) DE60226218T2 (da)
DK (2) DK1923071T3 (da)
ES (2) ES2428664T3 (da)
MX (1) MXPA03008287A (da)
NZ (1) NZ529012A (da)
PT (1) PT1372712E (da)
WO (1) WO2002074335A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
JP2005075752A (ja) * 2003-08-29 2005-03-24 Nippon Inst For Biological Science 豚繁殖・呼吸障害症候群用ワクチン製剤
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
CA2626875A1 (en) * 2005-11-01 2007-05-10 Intervet International B.V. Prime boost vaccine for the protection of equines against equine influenza
US9642908B2 (en) 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
CN102257135B (zh) 2008-12-16 2017-06-09 纳米医疗公司 流感疫苗的生产
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
ES2559445T3 (es) * 2010-05-11 2016-02-12 Intervet International B.V. Vacuna contra Mycoplasma hyopneumoniae apta para la administración en presencia de anticuerpos de origen materno
SI3542819T1 (sl) * 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
JP6560056B2 (ja) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
JP2018088928A (ja) * 2018-02-13 2018-06-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
US20250114447A1 (en) * 2021-08-06 2025-04-10 Intervet Inc. Vaccine for equine herpesvirus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4110433A (en) 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
US4083958A (en) 1976-09-13 1978-04-11 The University Of Kentucky Research Foundation Inactivated equine rhinopneumonitis virus vaccine and use thereof
US4225582A (en) 1979-03-08 1980-09-30 The University Of Illinois Foundation Vaccine for equine rhinopneumonitis
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US5084271B1 (en) 1984-09-11 1997-08-05 Univ Melbourne Vaccine for equine herpesvirus
US4758641A (en) 1987-02-24 1988-07-19 The B F Goodrich Company Polycarboxylic acids with small amount of residual monomer
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5221722A (en) 1988-11-28 1993-06-22 The B. F. Goodrich Company Crosslinked polyacrylic acid
US5292653A (en) * 1989-09-27 1994-03-08 Novagene, Inc. Equine herpesvirus 1 tk mutants
GB9014950D0 (en) 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US6025181A (en) 1990-07-06 2000-02-15 University Court Of The University Of Glasgow Equine herpesvirus-4TK mutant
WO1992002252A1 (en) * 1990-08-01 1992-02-20 Research Corporation Technologies, Inc. The gene encoding equine herpesvirus type 1 glycoprotein d, its gene product, antibodies and their uses
US5462734A (en) * 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
EP0532833A1 (en) * 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
DE69333416D1 (de) 1992-06-01 2004-03-18 Univ Melbourne Parkville Immunologisches Verfahren für die Detektion von Pferde-Herpesvirus Typ 1 und 4 glycoprotein G Antikörper
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
US6225111B1 (en) 1992-08-07 2001-05-01 Schering Plough Veterinary Corp. Recombinant equine herpesviruses
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US5853715A (en) * 1996-08-16 1998-12-29 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
DE59811284D1 (de) 1997-03-12 2004-06-03 Merck Patent Gmbh Endstück für eine chromatographische säule
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
EP0978286A1 (en) 1998-08-07 2000-02-09 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine

Also Published As

Publication number Publication date
CA2441292A1 (en) 2002-09-26
US20050084502A1 (en) 2005-04-21
WO2002074335A2 (en) 2002-09-26
US7226604B2 (en) 2007-06-05
JP2007197470A (ja) 2007-08-09
KR100840525B1 (ko) 2008-06-24
DK1372712T3 (da) 2008-08-04
US20070196390A1 (en) 2007-08-23
DE60226218D1 (de) 2008-06-05
DE60226218T2 (de) 2009-05-28
EP1372712B1 (en) 2008-04-23
CA2441292C (en) 2012-03-20
JP4177112B2 (ja) 2008-11-05
MXPA03008287A (es) 2004-10-28
CY1108200T1 (el) 2014-02-12
EP1923071B1 (en) 2013-06-19
JP4668951B2 (ja) 2011-04-13
AR032984A1 (es) 2003-12-03
KR20030085028A (ko) 2003-11-01
EP1923071A1 (en) 2008-05-21
ES2305220T3 (es) 2008-11-01
ATE392903T1 (de) 2008-05-15
US20030206924A1 (en) 2003-11-06
NZ529012A (en) 2005-08-26
WO2002074335A3 (en) 2003-07-17
AR091235A2 (es) 2015-01-21
JP2004525923A (ja) 2004-08-26
US6803041B2 (en) 2004-10-12
PT1372712E (pt) 2008-05-29
ES2428664T3 (es) 2013-11-08
EP1372712A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
DK1390066T3 (da) Vaccinesammensætning
DK1427444T3 (da) West-nil-vaccine
PL363005A1 (pl) Szczepionki
NO20031483L (no) Vaksine
NO20014325D0 (no) Vaksine
NO20024172D0 (no) Vaksine
DE60117735D1 (de) Pufferspeichersystem
GB0130215D0 (en) Vaccine
NO20033882D0 (no) Vaksine
GB0407935D0 (en) Vaccine
NO20020763L (no) Vaksine
EP1423141A4 (en) VACCINE
DE60002650D1 (de) Öladjuvierter Impfstoff
IS7831A (is) Bóluefni
DE60226366D1 (de) Pufferspeichersystem
GB0121171D0 (en) Vaccine
DE60226218D1 (de) Impfstoff gegen pferdeherpesvirus
DE60328408D1 (de) Impfstoff
EP1396455A4 (en) ELEVATION SYSTEM
NO20051561D0 (no) Vaksine
DE10290185D2 (de) Tumorvakzine
ITMI20021031A0 (it) Procedimento per preparare policarbonato-polioli
NO20011990D0 (no) Kreftvaksine
SE0101991D0 (sv) System & Förfarande
NO20012126D0 (no) HIV-vaksine